SCHEMBL20979999

SCHEMBL20979999

O=C(O)c1ccc(-c2ccc3cc(O)c(C4=C5CC6CC(C5)CC4C6)cc3c2)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.57
KMT2A Q03164 3/20 0.57
THRB P10828 1/20 0.57
RECQL P46063 1/20 0.57
NR2E1 Q9Y466 1/20 0.57
RARB P10826 13/20 0.46
RARG P13631 13/20 0.46
RARA P10276 8/20 0.46
KDM4E B2RXH2 2/20 0.46
HSD17B10 Q99714 2/20 0.46
ALDH1A1 P00352 1/20 0.46
TP53 P04637 1/20 0.46
CYP3A4 P08684 1/20 0.46
MAPT P10636 1/20 0.46
HPGD P15428 1/20 0.46
ALOX15 P16050 1/20 0.46
ALOX12 P18054 1/20 0.46
MAPK1 P28482 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
ERN1 O75460 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21482157 0.88 RARB (0.55) MEN1KMT2ATHRBRECQLNR2E1
SCHEMBL17169672 0.73 MEN1 (0.61) MEN1KMT2ATHRBRECQLNR2E1
SCHEMBL29359220 0.72 MEN1 (1.00) MEN1KMT2ATHRBRECQLNR2E1
SCHEMBL173380 0.72 MEN1 (1.00) MEN1KMT2ATHRBRECQLNR2E1
Methane SCHEMBL16147145 0.70 MEN1 (0.51) MEN1KMT2ATHRBRECQLNR2E1
SCHEMBL174449 0.70 MEN1 (0.51) MEN1KMT2ATHRBRECQLNR2E1
SCHEMBL14157072 0.70 MIF (0.57) MEN1KMT2ATHRBRECQLNR2E1
SCHEMBL1250065 0.70 ACMSD (0.57) MEN1KMT2ATHRBRECQLNR2E1
SCHEMBL3020401 0.69 ESR1 (0.67) MEN1KMT2ARARBRARGRARA
SCHEMBL19235986 0.68 MEN1 (0.70) MEN1KMT2ATHRBRECQLNR2E1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230255937-A1 THERAPEUTIC AGENT FOR KERATOCONJUNCTIVE DISORDERS YAMAGUCHI UNIVERSITY (JP) 2023-08-17 US disclosed
US-10537556-B2 Therapeutic agent for keratoconjunctive disorders YAMAGUCHI UNIVERSITY (JP) 2020-01-21 US disclosed
US-20190134002-A1 THERAPEUTIC AGENT FOR KERATOCONJUNCTIVE DISORDERS YAMAGUCHI UNIVERSITY (JP) 2019-05-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10537556-B2 Therapeutic agent for keratoconjunctive disorders RARG, RARB, RARA MEN1 4882/4885KMT2A 3104/4885THRB 382/4885
US-20230255937-A1 THERAPEUTIC AGENT FOR KERATOCONJUNCTIVE DISORDERS RARG, RARB, RARA MEN1 4882/4885KMT2A 3104/4885THRB 382/4885
US-20190134002-A1 THERAPEUTIC AGENT FOR KERATOCONJUNCTIVE DISORDERS RARG, RARB, RARA MEN1 4882/4885KMT2A 3104/4885THRB 382/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.